- Home
- PHGE vs YMAT Comparison
PHGE vs YMAT Comparison
Compare PHGE & YMAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHGE
- YMAT
- Stock Information
- Founded
- PHGE 2015
- YMAT 1970
- Country
- PHGE Israel
- YMAT Taiwan
- Employees
- PHGE N/A
- YMAT N/A
- Industry
- PHGE Biotechnology: Pharmaceutical Preparations
- YMAT Recreational Games/Products/Toys
- Sector
- PHGE Health Care
- YMAT Consumer Discretionary
- Exchange
- PHGE Nasdaq
- YMAT Nasdaq
- Market Cap
- PHGE 13.0M
- YMAT 15.3M
- IPO Year
- PHGE N/A
- YMAT 2025
- Fundamental
- Price
- PHGE $0.31
- YMAT $0.84
- Analyst Decision
- PHGE Strong Buy
- YMAT
- Analyst Count
- PHGE 1
- YMAT 0
- Target Price
- PHGE $15.00
- YMAT N/A
- AVG Volume (30 Days)
- PHGE 1.7M
- YMAT 2.0M
- Earning Date
- PHGE 11-12-2025
- YMAT 04-29-2026
- Dividend Yield
- PHGE N/A
- YMAT N/A
- EPS Growth
- PHGE N/A
- YMAT N/A
- EPS
- PHGE N/A
- YMAT 0.07
- Revenue
- PHGE N/A
- YMAT $17,563,985.00
- Revenue This Year
- PHGE N/A
- YMAT N/A
- Revenue Next Year
- PHGE N/A
- YMAT N/A
- P/E Ratio
- PHGE N/A
- YMAT $11.51
- Revenue Growth
- PHGE N/A
- YMAT N/A
- 52 Week Low
- PHGE $0.31
- YMAT $0.78
- 52 Week High
- PHGE $1.16
- YMAT $6.45
- Technical
- Relative Strength Index (RSI)
- PHGE 27.31
- YMAT N/A
- Support Level
- PHGE $0.35
- YMAT N/A
- Resistance Level
- PHGE $0.42
- YMAT N/A
- Average True Range (ATR)
- PHGE 0.04
- YMAT 0.00
- MACD
- PHGE -0.01
- YMAT 0.00
- Stochastic Oscillator
- PHGE 2.81
- YMAT 0.00
About PHGE BiomX Inc. COmmon Stock
BiomX Inc is engaged in developing both natural and engineered phage cocktails and personalized treatments designed to target and destroy harmful bacteria in chronic diseases, including cystic fibrosis and diabetic foot osteomyelitis. It discovers and validates proprietary bacterial targets and customizes phage compositions against these targets, and applies its BOLT (BacteriOphage Lead to Treatment) platform to customize phage compositions against these targets. BX004 is its therapeutic phage product candidate under development for chronic pulmonary infections caused by Pseudomonas aeruginosa, or P. aeruginosa, a main contributor to morbidity and mortality in patients with CF. Its BX211 - Treatment of Diabetic Foot Osteomyelitis (DFO).
About YMAT J-Star Holding Co. Ltd. Ordinary Shares
J Star Holding Co Ltd is engaged in the research, development and manufacturing of carbon fiber for a wide variety of products including carbon bicycles, carbon rackets, automotive parts, outdoor sports gears, and healthcare products.